Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurocrine Biosciences Inc (Nasdaq: NBIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, publicly traded biopharmaceutical company, Neurocrine Biosciences reports its financial performance, material events and key corporate developments through forms such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports.
In its recent Form 8-K filings, Neurocrine Biosciences has reported quarterly financial results, including net product sales for INGREZZA and CRENESSITY, research and development and selling, general and administrative expenses, and net income. These filings often incorporate press releases that discuss revenue trends, non-GAAP financial measures, R&D investment in programs such as osavampator and direclidine, and updates on collaborations. Other 8-K items may cover executive and board-related matters, such as amendments to employment agreements and changes in key leadership roles.
On this page, investors can review the full text of Neurocrine Biosciences’ periodic reports to understand how the company describes its business, risk factors, product portfolio and pipeline. The annual Form 10-K typically includes detailed sections on therapeutic focus areas like tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as discussion of the company’s neuroscience and endocrinology research strategy. Quarterly Form 10-Q filings update these disclosures and provide interim financial statements.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points from lengthy filings, helping readers quickly identify changes in revenue composition, R&D spending, collaboration milestones and other material items. Users can also monitor real-time 8-K updates for new clinical data announcements, financing activities or governance changes, and access Form 4 insider transaction reports to see how company insiders are trading NBIX shares, when such filings are available.
Whether you are evaluating Neurocrine Biosciences’ exposure to specific therapeutic areas, following its investment in late-stage programs like osavampator and direclidine, or comparing GAAP and non-GAAP results, this filings page offers a structured view of the company’s official SEC record with tools that make complex disclosures easier to interpret.
Neurocrine Biosciences (NBIX) reported an insider transaction. On 11/05/2025, a director exercised 18,000 non-qualified stock options at an exercise price of $47.89 per share and sold 18,000 common shares at a weighted average price of $151.8161. The sale was executed under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Following these transactions, the reporting person beneficially owned 40,360 shares, held by the Rastetter Family Trust. The option was granted on May 20, 2016 and was due to expire on May 20, 2026.
Neurocrine Biosciences (NBIX) CEO and director reported Form 4 activity. On 11/01/2025, 613 shares of common stock were acquired at $0 upon RSU vesting.
On 11/04/2025, 300 shares were sold at $141.97. The filing states these mandatory sales were made to cover withholding taxes and are intended to meet Rule 10b5-1(c). After these transactions, directly held shares were 140,407, and derivative holdings (RSUs) were 1,842. Beneficial ownership includes 200 shares purchased on 02/28/2025 under the company’s ESPP.
Neurocrine Biosciences reported strong Q3 2025 results, with total revenues of $794.9 million, up from $622.1 million a year ago. Growth was driven by INGREZZA net product sales of $686.6 million and the U.S. launch of CRENESSITY contributing $98.1 million. Operating income was $239.0 million and net income reached $209.5 million, translating to diluted EPS of $2.04 versus $1.24 last year.
The company continued to invest for growth: research and development expense rose to $250.0 million and selling, general, and administrative expense to $291.6 million. Year to date, cash flows from operating activities were $394.3 million. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $2,113.3 million, with working capital of $1,520.4 million. Neurocrine repurchased 1.8 million shares for $227.2 million during the first nine months of 2025 under its $500 million authorization and completed a $300 million accelerated repurchase begun in 2024. Shares outstanding were 99,705,698 as of October 21, 2025.
Neurocrine Biosciences, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025. The company disclosed this by filing a current report and attaching the full earnings press release as Exhibit 99.1. The press release, dated October 28, 2025, contains the detailed figures and discussion of its results of operations and financial condition for the quarter.
Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences, reported a non-market transfer of common stock on 09/03/2025. The filing shows 1,470 shares were disposed of as a gift/charitable contribution with no cash received, and 13,703 shares remained beneficially owned after the transaction. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and lists the transaction code as G(1), indicating a gift. No derivative securities were reported.
Stephen A. Sherwin, a director of Neurocrine Biosciences Inc. (NBIX), reported a non-market transfer of 1,000 shares of the company's common stock on 09/02/2025 coded as a gift (transaction code G(1)). The form shows $0 as the price because no cash was received for the gifted shares. After the transaction, Mr. Sherwin beneficially owned 12,542 shares, held directly. The filing was executed by attorney-in-fact Darin Lippoldt and dated 09/03/2025. The Form 4 discloses this change in beneficial ownership and follows Section 16 reporting requirements.
Dr. Kevin Charles Gorman, a director of Neurocrine Biosciences (NBIX), exercised 106,322 non-qualified stock options with an exercise price of $35.99 and sold 106,322 resulting shares on 08/07/2025. The sales were effected by a broker under a Rule 10b5-1 trading plan adopted on February 24, 2025, at a weighted-average price of $126.4111 per share (sales ranged $124.80–$129.03). After the transactions, Dr. Gorman beneficially owns 514,596 shares; 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which he has voting and investment power. The options were granted on February 5, 2016, vested in monthly installments, and were due to expire on February 5, 2026. The disposition was effected pursuant to the pre-arranged 10b5-1 plan and the issuer’s policy prevents amendment of that plan after adoption.